Boehringer Ingelheim reports strong growth in 2016 business year

Boehringer Ingelheim has announced its financial results for the 2016 business year, during which it generated a net sales total of 15.9 billion euros (13.58 billion pounds).

This represented a currency-adjusted year-on-year increase of 7.3 percent, with net sales increased across all business units. Operating income improved by 27 percent to around 2.9 billion euros, meaning the return on net sales came to 18.1 percent.

During the year, the firm was able to complete a significant transformation, having traded its consumer health division to Sanofi in exchange for ownership of the animal health business Merial.

Its pharmaceuticals business also achieved a strong performance, with encouraging sales of prescription medicines led by the blockbuster respiratory medication Spiriva.

In 2017, Boehringer Ingelheim is expecting a considerable year-on-year increase in currency-adjusted net sales, with the integration of the new animal health business to play a key role.

Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, said: "We look to the future with confidence – especially after successfully completing the transformation of our business."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.